CompletedPhase 4

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.

Lead sponsor

Hospital Civil Juan I. Menchaca

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Bariatric Surgery Candidate, Obesity / overweight

Eligibility highlights

•BMI ≥48

Primary endpoint

•Body weight, absolute change (kg)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06201819

Org study IDCEI-008-20161212

Timeline

Milestones

Study start2022-12-18actual

Primary completion2023-03-18actual

Study completion2023-05-01actual

Study first posted2024-01-11actual

Last update posted2024-01-18actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Bariatric Surgery CandidateObesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients with BMI greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the Bariatric and Metabolic Surgery Unit of the Civil Hospital of Guadalajara "Dr. Juan I. Menchaca

Exclusion criteria

•Patients under 18 years of age or over 65 years of age.

-Pregnant patients.

-Patients who do not agree to give their consent and take part in the study.

-Patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones.

Removal:

•Patients who decide to abandon the study.

•Patients who do not follow the instructions or do not adhere to the treatment.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Preoperative weight changes

Time frame:3 months

Body weight, absolute change (kg)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.